MIF as an oncogenic driver of low‐heterogeneity melanomas
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Thuy T Tran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Carcinogenesis, Intramolecular Oxidoreductases, Macrophage Migration-Inhibitory Factors, Melanoma. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCR NIH HHS, CSRD VA, Kuni Foundation Discovery Grant.
Abstract (Originalsprache)
Identifying targets involved in tumor evolution and immune escape is an active area of research in oncology. Macrophage migration inhibitory factor (MIF) is an upstream immunoregulatory cytokine that promotes transformed cell proliferation and survival, and generates a tumor‐permissive immune landscape of immunosuppressive myeloid and T cells. Shvefel and colleagues have identified a key role for MIF in tumor progression in melanoma clones with low tumor heterogeneity. These findings provide important insights into the potential therapeutic utility of MIF antagonists and support ongoing research to utilize MIF pathway inhibitors for improved therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
- Section of Rheumatology, Allergy & Immunology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
- Department of Dermatology, Oregon Health & Science University, Portland, OR, USA.
ORCID-Profile: Thuy T Tran, Harriet M Kluger
Förderung
- NIDCR NIH HHS
- CSRD VA
- Kuni Foundation Discovery Grant
- Karin Bain and John Kukral Foundation
- National Institute of Health
- NCI NIH HHS
- U.S. Department of Veterans Affairs
Zitieren
APA
Tran, T. T., Sánchez-Zuno, G. A., Kulkarni, R. P., Kluger, H. M., & Bucala, R. (2025). MIF as an oncogenic driver of low‐heterogeneity melanomas. Molecular Oncology. https://doi.org/10.1002/1878-0261.70031
Vancouver
Tran TT, Sánchez-Zuno GA, Kulkarni RP, Kluger HM, Bucala R. MIF as an oncogenic driver of low‐heterogeneity melanomas. Molecular Oncology. 2025. doi:10.1002/1878-0261.70031
BibTeX
@article{Tran2025,
author = {Tran, Thuy T and Sánchez-Zuno, Gabriela Athziri and Kulkarni, Rajan P and Kluger, Harriet M and Bucala, Richard},
title = {MIF as an oncogenic driver of low‐heterogeneity melanomas},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70031}
}
EUVIMED